Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Endocrine 4NET 2

Conditions

Neuroendocrine Tumors 11Somatostatinoma 6Insulinoma 4Glucagonoma 4Gastrinoma 4Carcinoma, Neuroendocrine 4Carcinoma, Islet Cell 3Zollinger-Ellison Syndrome 2Vipoma 2Pheochromocytoma 2Pancreatic Neoplasms 2Carcinoma, Medullary 2Carcinoid Tumor 2Adenoma, Islet Cell 2Pituitary Neoplasms 1Non functioning pancreatic endocrine tumor 1Neoplasms 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Gastro-enteropancreatic neuroendocrine tumor 1Gastro-entero-pancreatic Neuroendocrine Tumors 1Carcinoma, Merkel Cell 1Adrenal Cortex Neoplasms 1

Interventions

Cisplatin 12Everolimus 10Nivolumab 8Etoposide 8Temozolomide 6Carboplatin 6atezolizumab 5Irinotecan 5Ipilimumab 5Fluorouracil 5Bevacizumab 5pembrolizumab 4lutetium Lu 177 dotatate 4Capecitabine 4avelumab 3Paclitaxel 3IFL protocol 3surufatinib 2sintilimab 2gallium Ga 68 dotatate 2dostarlimab 2cabozantinib 2belinostat 2azaspirane 2Topotecan 2Radiosurgery 2Positron Emission Tomography Computed Tomography 2PE regimen 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Magnetic Resonance Imaging 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Capecitabine × Endocrine × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

NCT03387592 2025-03-10

SENECA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated
53 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT03079440 2022-12-06

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Asan Medical Center

Phase 2 Completed
31 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

NCT01203306 2010-09-16

XELBEVOCT

University of Turin, Italy

Phase 2 Unknown
42 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡